Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Ascendis Pharma ( (ASND) ) is now available.
On May 12, 2026, Ascendis Pharma A/S granted 31,250 new employee warrants, each exercisable into one ordinary share at an exercise price of $237.65, equal to the closing share price on the grant date. The company amended its Articles of Association to enable this issuance, which features a four-year vesting schedule with 25% vesting after one year and the remainder vesting monthly, reinforcing its long-term incentive structure.
Following this grant, Ascendis Pharma still has outstanding authorization to issue warrants for an additional 1,580,593 shares under its Articles of Association, preserving significant capacity for future equity-based compensation. The move underscores the company’s continued reliance on share-linked incentives to attract and retain key employees, with potential dilution implications that current and prospective shareholders will monitor as the remaining warrant pool is deployed.
The most recent analyst rating on (ASND) stock is a Buy with a $345.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving operating/free cash flow and strong commercial momentum highlighted on the earnings call, tempered by meaningful balance-sheet leverage and mixed earnings quality. Technicals add support via an established uptrend, and valuation looks favorable given the low P/E.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing, manufacturing, and commercializing medical treatments aimed at combating disease. The company’s activities include owning stakes in related businesses and pursuing initiatives that are naturally connected to its core drug development and commercialization efforts.
Average Trading Volume: 693,976
Technical Sentiment Signal: Buy
Current Market Cap: $14.82B
See more data about ASND stock on TipRanks’ Stock Analysis page.